Artificial intelligence for medicine: people, society, pharmaceuticals, and medical materials
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Berlin
De Gruyter
[2022]
|
| Schriftenreihe: | De Gruyter STEM
|
| Schlagworte: | |
| Online-Zugang: | https://www.degruyter.com/books/9783110717792 Inhaltsverzeichnis Inhaltsverzeichnis |
| Beschreibung: | XXVII, 490 Seiten Illustrationen 24 cm x 17 cm |
| ISBN: | 9783110717792 3110717794 |
Internformat
MARC
| LEADER | 00000nam a22000008c 4500 | ||
|---|---|---|---|
| 001 | BV047583848 | ||
| 003 | DE-604 | ||
| 005 | 20231212 | ||
| 007 | t| | ||
| 008 | 211111s2022 gw a||| |||| 00||| eng d | ||
| 015 | |a 21,N06 |2 dnb | ||
| 016 | 7 | |a 1226451152 |2 DE-101 | |
| 020 | |a 9783110717792 |c : EUR 86.95 (DE) (freier Preis), EUR 86.95 (AT) (freier Preis) |9 978-3-11-071779-2 | ||
| 020 | |a 3110717794 |9 3-11-071779-4 | ||
| 024 | 3 | |a 9783110717792 | |
| 035 | |a (OCoLC)1286877087 | ||
| 035 | |a (DE-599)DNB1226451152 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-BE | ||
| 049 | |a DE-384 |a DE-573 |a DE-898 |a DE-29T |a DE-29 |a DE-M347 | ||
| 084 | |a XC 4000 |0 (DE-625)152514:12905 |2 rvk | ||
| 084 | |a 660 |2 23sdnb | ||
| 100 | 1 | |a Oshida, Yoshiki |0 (DE-588)1225432790 |4 aut | |
| 245 | 1 | 0 | |a Artificial intelligence for medicine |b people, society, pharmaceuticals, and medical materials |c Yoshiki Oshida |
| 264 | 1 | |a Berlin |b De Gruyter |c [2022] | |
| 300 | |a XXVII, 490 Seiten |b Illustrationen |c 24 cm x 17 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a De Gruyter STEM | |
| 650 | 0 | 7 | |a Künstliche Intelligenz |0 (DE-588)4033447-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Medizin |0 (DE-588)4038243-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittel |0 (DE-588)4003115-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Gesellschaft |0 (DE-588)4020588-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Medizinische Versorgung |0 (DE-588)4038270-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Intelligenter Werkstoff |0 (DE-588)4274825-2 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Künstliche Intelligenz |0 (DE-588)4033447-8 |D s |
| 689 | 0 | 1 | |a Medizinische Versorgung |0 (DE-588)4038270-9 |D s |
| 689 | 0 | 2 | |a Gesellschaft |0 (DE-588)4020588-5 |D s |
| 689 | 0 | 3 | |a Arzneimittel |0 (DE-588)4003115-9 |D s |
| 689 | 0 | 4 | |a Intelligenter Werkstoff |0 (DE-588)4274825-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Medizin |0 (DE-588)4038243-6 |D s |
| 689 | 1 | 1 | |a Künstliche Intelligenz |0 (DE-588)4033447-8 |D s |
| 689 | 1 | |5 DE-604 | |
| 710 | 2 | |a Walter de Gruyter GmbH & Co. KG |0 (DE-588)10095502-2 |4 pbl | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe |z 978-3-11-071785-3 |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe |z 978-3-11-071792-1 |
| 856 | 4 | 2 | |m X:MVB |u https://www.degruyter.com/books/9783110717792 |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032969182&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 856 | 4 | 2 | |m Digitalisierung UB Augsburg - ADAM Catalogue Enrichment |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032969182&sequence=000003&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-032969182 | |
Datensatz im Suchindex
| _version_ | 1816888268725157888 |
|---|---|
| adam_text |
CONTENTS
PREFACE
-
V
LIST
OF
ABBREVIATIONS
-
XIX
ABOUT
THE
AUTHOR
----
XXIX
CHAPTER
1
AL
IN
GENERAL
-
1
1.1
1.2
1.3
1.3.1
1.3.2
1.4
1.4.1
1.4.2
1.5
1.5.1
1.5.2
1.5.3
1.5.4
1.6
1.6.1
1.6.2
UNDEFINED
DEFINITION
-
1
HISTORY
OF
AL
DEVELOPMENT
AND
FUTURE
----
2
NATURE
----
5
IN
GENERAL
-
5
AS
A
PART
OF
IT
----
7
CLASSIFICATION
-
8
ELEMENTAL
TECHNOLOGIES
INVOLVED
IN
AL
-----8
THREE
ALS
----
11
ROLE,
FUNCTION,
AND
APPLICATIONS
OF
AL
----
13
ROLE
----
13
FUNCTION
-
14
SUPPORTING
TECHNOLOGIES
----
14
APPLICATIONS
----
17
ADVANTAGES
AND
DISADVANTAGES
----
18
ADVANTAGES
----
18
DISADVANTAGES
----
18
REFERENCES
----
19
CHAPTER
2
AL
IN
INFORMATION
----
23
2.1
2.1.1
2.1.2
2.2
2.3
DATA
VERSUS
INFORMATION
----
23
DATA
----
24
DATA
MINING,
INFORMATION,
AND
DIKW
HIERARCHY
----
25
KNOWLEDGE,
INTELLIGENCE,
AND
INTELLECT
----
26
AL
ONTOLOGY
----
29
REFERENCES
----
30
CHAPTER
3
AL
IN
SOCIETY
----
32
3.1
3.2
GLOBAL
----
32
SOCIETAL
----
35
XII
-
CONTENTS
3.3
PERSONAL
-----
37
3.3.1
TECHNOLOGICAL
ENVIRONMENT
---
37
3.3.2
EXAMPLES
OF
JOBS
THAT
ARE
LIKELY
TO
BE
SUBSTITUTED
BY
AL
----
39
3.3.3
REPRESENTATIVE
EXAMPLES
OF
LESS
LIKELY
POSITIONS
TO
BE
SUBSTITUTED
BY
AL
----
40
3.3.4
NEW-TYPE
JOBS
THAT
AL
CREATES
-----
41
3.3.5
WORK-STYLE
REFORMATION
-----42
3.4
FUTURE
OF
AL
SOCIETY
-----
43
REFERENCES
----
44
CHAPTER
4
AL
IN
CONCERN
-
47
4.1
DIGITAL
CLONE
----
47
4.2
PERSONALITY
----
49
4.2.1
LEGAL
PERSONALITY
-----
49
4.2.2
PERSONALITY
----
50
4.2.3
CONSCIOUSNESS,
GENDER,
AND
MARRIAGE
----
50
4.3
IQ
AND
COMMON
SENSE
----
52
4.3.1
IQ
TEST
----
52
4.3.2
COMMON
SENSE
-----
54
4.3.3
LIE
AND
SONTAKU
-----
55
4.4
BIAS
AND
ERRORS
-----
57
4.4.1
BIAS
----
57
4.4.2
ERRORS
----
58
4.4.3
COMPUTER
VIRUS
AND
IMMUNE
SYSTEM
----
60
4.5
EQ
AND
ETHICS
-----
61
4.5.1
EQ----
62
4.5.2
ETHICS
----
63
4.5.3
ACCOUNTABILITY
-----
65
4.6
PRIVACY
AND
ITS
RELATED
ISSUES
----
67
4.6.1
PRIVACY
----
67
4.6.2
TRANSPARENCY
AND
EXPLAINABILITY
68
4.7
COPYRIGHT
----
69
4.8
SINGULARITY
AND
OTHER
CONCERNS
----
72
4.8.1
SUPERINTELLIGENCE
AND
SINGULARITY
72
4.8.2
OTHER
CONCERNS
-----
75
REFERENCES
-
76
CHAPTER
5
AL
IN
LIFE:
FROM
CRADLE
TO
GRAVE
----
82
5.1
PREGNANCY
AND
POST-DELIVERY
-----83
5.1.1
INFERTILITY
TREATMENT
-----83
CONTENTS
-
XIII
5.1.2
5.1.3
5.2
5.3
5.4
5.5
5.5.1
5.5.2
SPERM
AND
EMBRYO
CULTURING
----
86
PREGNANT
WOMAN
SUPPORT
-
87
OBSTETRICS
AND
GYNECOLOGY
(OB/GYN)
----
88
PEDIATRICS
----
90
DAILY
LIFE
-
92
NCDS
AND
FRAILTY
----
93
NCDS
-----94
FRAILTY
----
95
REFERENCES
----
98
CHAPTER
6
AL
IN
QOL
(QUALITY
OF
LIVING),
QOS
(QUALITY
OF
SLEEPING),
AND
QOD
(QUALITY
OF
DYING)
----
101
6.1
6.1.1
6.1.2
6.2
6.2.1
6.2.2
6.2.3
6.2.4
6.3
QUALITY
OF
LIVING
(QOL)
----
101
QOL
BY
GENERAL
HEALTHCARE
----
103
QOL
BY
CHECKING
EXCRETIONS/SECRETIONS
----
104
QUALITY
OF
SLEEP
(QOS)
----
107
CHECKING
QUALITY
OF
SLEEP
----
108
HEADBAND
----
109
ARMBAND
----
109
BED
AND
MATTRESS
----
109
QUALITY
OF
DYING
(QOD)
----
110
REFERENCES
----
114
CHAPTER?
AL
IN
FOOD
INDUSTRY
----
118
7.1
7.1.1
7.1.2
7.2
7.2.1
7.2.2
7.3
7.3.1
7.3.2
7.3.3
7.3.4
7.4
7.4.1
7.4.2
7.5
FOOD
INDUSTRY
AND
BIODIVERSITY
----
118
FOOD
INDUSTRY
----
118
BIODIVERSITY
----
119
AGRICULTURE
INDUSTRY
----
120
OUTDOOR
FIELD
AGRICULTURE
----
120
INDOOR
VEGETABLE
FACTORY
----
122
ANIMAL
HUSBANDRY
----
124
LIVESTOCK
INDUSTRY
----
128
DAIRY
INDUSTRY
----
128
POULTRY
INDUSTRY
----
129
GIBIER
----
131
MARINE
PRODUCTS
INDUSTRY
----
132
NATURAL
OCEAN
FISH
CATCHING
----
132
AQUACULTURE
----
133
SUPPLY
MECHANISM
AND
DRONE
DELIVERY
----
136
XIV
CONTENTS
7.6
FUNCTIONAL
FOODS
----
137
7.7
FOOD
SAFETY
AND
WASTE
-----
140
7.8
AL-SUPPORTED
FOOD
TECHNOLOGY
----
142
7.9
YOU
ARE
WHAT
YOU
EAT
-----
143
REFERENCES
----
146
COFFEE
BREAK:
INFORMATION
DIABETES
-
153
REFERENCES
----
156
CHAPTER
8
AL
IN
PRACTICE
OF
MEDICINE
-
158
8.1
INTRODUCTION
----
158
8.2
AL
MEDICINE
VERSUS
ES
MEDICINE
-----
162
8.3
PREVENTIVE
MEDICINE
----
164
8.3.1
PREVENTION
----
164
8.3.2
PREDICTION
-----
168
8.4
DIAGNOSIS
-----
169
8.4.1
INTRODUCTION
----
169
8.4.2
DIAGNOSIS
-----
171
8.4.3
DIAGNOSIS
CASES
----
174
8.4.4
AL
DIAGNOSIS
VERSUS
DOCTOR
DIAGNOSIS
----
211
8.4.5
IATROGENESIS
----
217
8.5
TRIAGE
----
217
8.5.1
TRIAGE
IN
GENERAL
----
217
8.5.2
TRIAGE
IN
COVID-19
ERA
----
222
8.6
TREATMENT,
PRECISION
MEDICINE,
PAIN
MANAGEMENT
----
223
8.6.1
TREATMENT
CASES
----
223
8.6.2
PRECISION
MEDICINE
AND
EDGE-AI
-----
238
8.6.3
PAIN
MANAGEMENT
----
244
8.6.4
ALLERGY
----
253
8.6.5
DRUG
DEVELOPMENT
----
256
8.6.6
MEDICAL
CARE
OPERATIONS
----
256
8.6.7
SURGICAL
ROBOT
TECHNOLOGIES
-------
261
8.7
PROGNOSIS
----
264
8.7.1
DIAGNOSIS
AND
PROGNOSIS
-----
264
8.7.2
REMAINING
LIFE
PREDICTION
-----
267
8.8
SPORTS
MEDICINE
----
271
8.9
COSMETIC
SURGERY
----
273
8.10
CONCERNS
AND
FUTURE
----
274
8.10.1
CONCERNS
----
275
8.10.2
FUTURE
----
277
REFERENCES
----
277
CONTENTS
-
YY
XV
CHAPTER
9
AL
IN
PRACTICE
OF
DENTISTRY
-
302
9.1
DENTISTRY
VERSUS
MEDICINE
-----
302
9.2
AL
DENTISTRY
-----
304
9.2.1
DIGITAL
DENTISTRY
----
304
9.2.2
HEALTH
DATA
MANAGEMENT
-----
305
9.2.3
AL
DENTISTRY
-----
308
9.3
AL
DENTAL
DISCIPLINES
----
311
9.3.1
IMPLANTOLOGY
-----
311
9.3.2
PROSTHODONTICS
-----
313
9.3.3
ORTHODONTICS
-----
314
9.3.4
PERIODONTICS
-----
322
9.3.5
ENDODONTICS
-----
323
9.3.6
PEDIATRIC
DENTISTRY
----
324
9.3.7
ORAL
CANCERS
-----
325
9.3.8
RADIOLOGY
-----
325
9.4
AL
DENTAL
LABORATORY
AND
TECHNICIANS
----
328
9.5
CLINICAL
RECORDING
AND
DATA
SECURITY
----
330
9.5.1
SOAP
----
330
9.5.2
POS/POMR----
332
9.5.3
PKC
----
333
9.5.4
HIPAA
----
334
9.6
ADVANCED
DENTISTRY
IN
FUTURE
----
336
9.6.1
DENTISTRY
IN
GENERAL
----
336
9.6.2
DIGITAL
DENTISTRY
----
337
9.6.3
TELEDENTISTRY
----
340
9.6.4
SYSTEMIC
TREATMENT
----
342
REFERENCES
----
346
CHAPTER
10
AL
IN
DRUG
DEVELOPMENT
-
356
10.1
AL-ASSISTED
NEW
DRUG
DEVELOPMENT
----
357
10.1.1
DRUG
DESIGN
----
358
10.1.2
TARGET
IDENTIFICATION
----
360
10.1.3
LEAD
COMPOUND
IDENTIFICATION
----
362
10.1.4
CLINICAL
RESEARCH
----
364
10.1.5
OVERALL
----
366
10.1.6
COVID-19
VACCINE
DEVELOPMENT
-----
368
10.1.7
FUTURE
ACTIVITIES
----
370
10.2
AL-INCORPORATED
DRUG
DELIVERY
SYSTEMS
----
374
10.3
SIDE
EFFECT
AND
DRUG
REPOSITIONING
----
376
XVI
-
CONTENTS
10.3.1
SIDE
EFFECT
AND
ITS
PREDICTION
----
376
10.3.2
DRUG
REPOSITIONING
----
380
10.3.3
BIOSIMILAR
AND
GENERIC
DRUGS
-----
383
10.4
DRUG
INFORMATION
MANAGEMENT
AND
PHARMACIST
----
385
10.4.1
DRUG
INFORMATION
MANAGEMENT
-----
385
10.4.2
PRESCRIPTION
ERRORS
AND
MANAGEMENT
----
386
10.4.3
ROLE
OF
PHARMACISTS
-------
389
10.5
PLACEBO
EFFECT
AND
NOCEBO
EFFECT
-----
390
10.5.1
PLACEBO
EFFECT
-----
390
10.5.2
NOCEBO
EFFECT
-----
393
REFERENCES
----
395
CHAPTER
11
AL
IN
MATERIALS
SCIENCE
AND
DEVELOPMENT
-
402
11.1
AL-ASSISTED
MATERIALS
SCIENCE
-----
402
11.2
SMART
MATERIALS
----
404
11.3
AL-ASSISTED
MATERIALS
DESIGN
AND
DEVELOPMENT
-----
405
REFERENCES
-
411
CHAPTER
12
AL
IN
COVID-19
ERA,
INFODEMIC,
AND
POST-COVID-19
ERA
----
414
12.1
WITH
COVID-19
----
414
12.2
SOME
CONCERNS
AND
INFODEMIC
----
420
12.2.1
CONCERNS
----
420
12.2.2
INFODEMIC
----
422
12.3
POST
COVID-19
-----
424
REFERENCES
----
428
CHAPTER
13
AL
IN
FUTURE
----
431
13.1
PRESENT
AND
FUTURE
OF
AL
TECHNOLOGY
----
432
13.1.1
REINFORCEMENT
LEARNING
(RL)
----
432
13.1.2
GENERATIVE
ADVERSARIAL
NETWORKS
(GAN)
----
436
13.1.3
DRASTIC
CHANGE
IN
EMPLOYMENT
SECTOR
AND
SOCIETY
----
439
13.1.4
AUTOMATED
TRANSPORTATION
-----
440
13.2
ECOSYSTEM
----
442
13.3
BIOINFORMATICS
AND
ALIFE
-----
443
13.3.1
BIOINFORMATICS
----
443
13.3.2
ALIFE
----
446
13.4
MEDICINE
----
447
13.4.1
VOLUMETRIC
DISPLAY
TECHNOLOGY
----
447
13.4.2
PARITY
MIRROR
IMAGING
-----
450
CONTENTS
-
XVII
13.5
BRAIN-COMPUTER
INTERFACE
(BCI)
-
451
13.5.1
CONSCIOUSNESS
OF
ROBOT
----
451
13.5.2
HUMAN-ROBOT
INTERACTION
----
454
13.6
PREDICTION
AND
SINGULARITY
-
457
13.6.1
PREDICTION
BEFORE
SINGULARITY
----
457
13.6.2
SINGULARITY
AND
BEYOND
----
462
13.7
QUANTUM
COMPUTERS
----
463
REFERENCES
-
465
CLOSING
REMARKS
----
472
REFERENCES
----
473
INDEX
----
475
Contents Preface — V List of abbreviations — XIX About the Author-----XXIX Chapter 1 Al in general---- 1 1.1 Undefined definition---- 1 1.2 History of Al development and future---- 2 1.3 Nature-----5 1.3.1 Ingenerai----- 5 1.3.2 As a part of IT----- 7 1.4 Classification----- 8 1.4.1 Elemental technologies involved in Al----- 8 1.4.2 Three Als----- 11 1.5 Role, function, and applications of Al----- 13 1.5.1 Role---- 13 1.5.2 Function----- 14 1.5.3 Supporting technologies---- 14 1.5.4 Applications----- 17 1.6 Advantages and disadvantages —18 1.6.1 Advantages----- 18 1.6.2 Disadvantages---- 18 References-----19 Chapter 2 Al in information---- 23 2.1 Data versus information---- 23 2.1.1 Data---- 24 2.1.2 Data mining, information, and DIKW hierarchy 2.2 Knowledge, intelligence, and intellect---- 26 2.3 Al ontology-----29 References-----30 Chapter 3 Al in society---- 32 3.1 Global-----32 3.2 Societal---35
ХИ — 3.3 3.3.1 3.3.2 3.3.3 3.3.4 3.3.5 3.4 Contents Personal----- 37 Technological environment----- 37 Examples of jobs that are likely to be substituted by Al Representative examples of less likely positions to be substituted by Al---- 40 New-type jobs that Al creates----- 41 Work-style reformation-----42 Future of Al society----- 43 References---- 44 Chapter 4 Al in concern---- 47 Digital clone---- 47 4.1 Personality-----49 4.2 Legal personality---- 49 4.2.1 Personality---- 50 4.2.2 Consciousness, gender, and marriage-----50 4.2.3 IQ and common sense---- 52 4.3 IQ test---- 52 4.3.1 Common sense-----54 4.3.2 4.3.3 Lie and Sontaku-----55 4.4 Bias and errors-----57 4.4.1 Bias-----57 4.4.2 Errors---- 58 4.4.3 Computer virus and immune system-----60 4.5 EQ and ethics---- 61 4.5.1 EQ---- 62 4.5.2 Ethics---- 63 4.5.3 Accountability---- 65 4.6 Privacy and its related issues-----67 4.6.1 Privacy---- 67 4.6.2 Transparency and explainability-----68 4.7 Copyright-----69 4.8 Singularity and other concerns-----72 4.8.1 Superintelligent and singularity-----72 4.8.2 Other concerns-----75 References-----76 Chapter 5 Al in life: from cradle to grave---- 82 5-1 Pregnancy and post-delivery----- 83 5.1.1 Infertility treatment------83
Contents 5.1.2 5.1.3 5.2 5.3 5.4 5.5 5.5.1 5.5.2 Sperm and embryo culturing---- 86 Pregnant woman support-----87 Obstetrics and gynecology (OB/GYN)-----88 Pediatrics---- 90 Daily life---- 92 NCDs and frailty---- 93 NCDs---- 94 Frailty---- 95 References---- 98 Chapter 6 Al in QOL (quality of living), QOS (quality of sleeping), and QOD (quality of dying)---- 101 6.1 Quality of living (QOL)---- 101 6.1.1 QOL by general healthcare---- 103 6.1.2 QOL by checking excretions/secretions---- 104 6.2 Quality of sleep (QOS)----- 107 6.2.1 Checking quality of sleep---- 108 6.2.2 Headband---- 109 6.2.3 Armband---- 109 6.2.4 Bed and mattress---- 109 6.3 Quality of dying (QOD)------ 110 References---- 114 Chapter 7 Al in food industry---- 118 7.1 Food industry and biodiversity-----118 7.1.1 Food industry----- 118 7.1.2 Biodiversity----- 119 7.2 Agriculture industry---- 120 7.2.1 Outdoor field agriculture----- 120 7.2.2 Indoor vegetable factory----- 122 7.3 Animal husbandry----- 124 7.3.1 Livestock industry---- 128 7.3.2 Dairy industry----- 128 7.3.3 Poultry industry---- 129 7.3.4 Gibier---- 131 7.4 Marine products industry---- 132 7.4.1 Natural ocean fish catching---- 132 7.4.2 Aquaculture----- 133 7.5 Supply mechanism and drone delivery---- 136 XIII
XIV ----- 7.6 7.7 7.8 7.9 Contents Functional foods-—137 Food safety and waste —■ 140 Al-supported food technology------142 You are what you eat-----143 References---- 146 Coffee break: information diabetes----- 153 References---- 156 Chapter 8 Al in practice of medicine----- 158 8.1 8.2 8.3 8.3.1 8.3.2 8.4 8.4.1 8.4.2 8.4.3 8.4.4 8.4.5 8.5 8.5.1 8.5.2 8.6 8.6.1 8.6.2 8.6.3 8.6.4 8.6.5 8.6.6 8.6.7 8.7 8.7.1 8.7.2 8.8 8.9 8.10 8.10.1 8.10.2 Introduction-----158 Al medicine versus ES medicine-----162 Preventive medicine------ 164 Prevention---- 164 Prediction-----168 Diagnosis----- 169 Introduction-----169 Diagnosis----- 171 Diagnosis cases---- 174 Al diagnosis versus doctor diagnosis-----211 Iatrogenesis---- 217 Triage-----217 Triage in general---- 217 Triage in COVID-19 era----- 222 Treatment, precision medicine, pain management-----223 Treatment cases---- 223 Precision medicineand Edge-AI------238 Pain management-244 Allergy----- 253 Drug development----- 256 Medical care operations----- 256 Surgical robot technologies---- 261 Prognosis-----264 Diagnosis and prognosis------264 Remaining life prediction---- 267 Sports medicine----- 271 Cosmetic surgery-----273 Concerns and future----- 274 Concerns---- 275 Future----- 277 References-----277
Chapter 9 Al in practice of dentistry----- 302 9.1 9.2 Dentistry versus medicine----- 302 Al dentistry----- 304 9.2.1 Digital dentistry----- 304 9.2.2 Health data management----- 305 9.2.3 Al dentistry------ 308 9.3 9.3.1 Al dental disciplines----- 311 Implantology------ 311 9.3.2 Prosthodontics----- 313 9.3.3 Orthodontics------ 314 9.3.4 Periodontics------322 9.3.5 Endodontics------ 323 9.3.6 Pediatric dentistry----- 324 9.3.7 Oral cancers------ 325 9.3.8 Radiology----- 325 9.4 Al dental laboratory and technicians----- 328 9.5 9.5.1 Clinical recording and data security----- 330 SOAP----- 330 9.5.2 POS/POMR------ 332 9.5.3 PKC----- 333 9.5.4 HIPAA----- 334 9.6 Advanced dentistry in future----- 336 9.6.1 Dentistry in general — 336 9.6.2 Digital dentistry----- 337 9.6.3 Teledentistry------ 340 9.6.4 Systemic treatment----- 342 References----- 346 Chapter 10 Al in drug development — 356 10.1 Al-assisted new drug development----- 357 10.1.1 Drug design----- 358 10.1.2 Target identification — 360 10.1.3 Lead compound identification----- 362 10.1.4 Clinical research----- 364 10.1.5 Overall----- 366 10.1.6 10.1.7 COVID-19 vaccine development----- 368 Future activities----- 370 10.2 Al-incorporated drug delivery systems-----374 10.3 Side effect and drug repositioning----- 376
XVI ---- 10.3.1 10.3.2 10.3.3 10.4 10.4.1 10.4.2 10.4.3 10.5 10.5.1 10.5.2 Contents Side effect and its prediction----- 376 Drug repositioning---- 380 Biosimilar and generic drugs----- 383 Drug information management and pharmacist Drug information management-----385 Prescription errors and management-----386 Role of pharmacists---- 389 Placebo effect and nocebo effect-----390 Placebo effect---- 390 Nocebo effect---- 393 References---- 395 385 Chapter 11 Al in materials science and development-----402 11.1 Al-assisted materials science---- 402 11.2 Smart materials-----404 11.3 Al-assisted materials design and development------ 405 References-----411 Chapter 12 Al in COVID -19 era, infodemic, and post-COVID-19 era 12.1 With COVID-19---- 414 12.2 Some concerns and infodemic-----420 12.2.1 Concerns---- 420 12.2.2 Infodemic---- 422 12.3 Post COVID-19---- 424 References---- 428 Chapter 13 Al in future ---- 431 13.1 Present and future of Al technology-----432 13.1.1 Reinforcement learning (RL)-----432 13.1.2 Generative adversarial networks (GAN)-----436 13.1.3 Drastic change in employment sector and society-----439 13.1.4 Automated transportation---- 440 13.2 Ecosystem---- 442 13.3 Bioinformatics and ALife-----443 13.3.1 Bioinformatics---- 443 13.3.2 ALife---- 446 13.4 Medicine-----447 13.4.1 Volumetric display technology---- 447 13.4.2 Parity mirror imaging---- 450
Contents 13.5 13.5.1 13.5.2 13.6 13.6.1 13.6.2 13.7 Brain-computer interface (ВСІ)-----451 Consciousness of robot------451 Human-robot interaction------454 Prediction and singularity------457 Prediction before singularity-----457 Singularity and beyond------462 Quantum computers-----463 References-----465 Closing remarks----- 472 References-----473 Index----- 475 — XVII |
| adam_txt |
CONTENTS
PREFACE
-
V
LIST
OF
ABBREVIATIONS
-
XIX
ABOUT
THE
AUTHOR
----
XXIX
CHAPTER
1
AL
IN
GENERAL
-
1
1.1
1.2
1.3
1.3.1
1.3.2
1.4
1.4.1
1.4.2
1.5
1.5.1
1.5.2
1.5.3
1.5.4
1.6
1.6.1
1.6.2
UNDEFINED
DEFINITION
-
1
HISTORY
OF
AL
DEVELOPMENT
AND
FUTURE
----
2
NATURE
----
5
IN
GENERAL
-
5
AS
A
PART
OF
IT
----
7
CLASSIFICATION
-
8
ELEMENTAL
TECHNOLOGIES
INVOLVED
IN
AL
-----8
THREE
ALS
----
11
ROLE,
FUNCTION,
AND
APPLICATIONS
OF
AL
----
13
ROLE
----
13
FUNCTION
-
14
SUPPORTING
TECHNOLOGIES
----
14
APPLICATIONS
----
17
ADVANTAGES
AND
DISADVANTAGES
----
18
ADVANTAGES
----
18
DISADVANTAGES
----
18
REFERENCES
----
19
CHAPTER
2
AL
IN
INFORMATION
----
23
2.1
2.1.1
2.1.2
2.2
2.3
DATA
VERSUS
INFORMATION
----
23
DATA
----
24
DATA
MINING,
INFORMATION,
AND
DIKW
HIERARCHY
----
25
KNOWLEDGE,
INTELLIGENCE,
AND
INTELLECT
----
26
AL
ONTOLOGY
----
29
REFERENCES
----
30
CHAPTER
3
AL
IN
SOCIETY
----
32
3.1
3.2
GLOBAL
----
32
SOCIETAL
----
35
XII
-
CONTENTS
3.3
PERSONAL
-----
37
3.3.1
TECHNOLOGICAL
ENVIRONMENT
---
37
3.3.2
EXAMPLES
OF
JOBS
THAT
ARE
LIKELY
TO
BE
SUBSTITUTED
BY
AL
----
39
3.3.3
REPRESENTATIVE
EXAMPLES
OF
LESS
LIKELY
POSITIONS
TO
BE
SUBSTITUTED
BY
AL
----
40
3.3.4
NEW-TYPE
JOBS
THAT
AL
CREATES
-----
41
3.3.5
WORK-STYLE
REFORMATION
-----42
3.4
FUTURE
OF
AL
SOCIETY
-----
43
REFERENCES
----
44
CHAPTER
4
AL
IN
CONCERN
-
47
4.1
DIGITAL
CLONE
----
47
4.2
PERSONALITY
----
49
4.2.1
LEGAL
PERSONALITY
-----
49
4.2.2
PERSONALITY
----
50
4.2.3
CONSCIOUSNESS,
GENDER,
AND
MARRIAGE
----
50
4.3
IQ
AND
COMMON
SENSE
----
52
4.3.1
IQ
TEST
----
52
4.3.2
COMMON
SENSE
-----
54
4.3.3
LIE
AND
SONTAKU
-----
55
4.4
BIAS
AND
ERRORS
-----
57
4.4.1
BIAS
----
57
4.4.2
ERRORS
----
58
4.4.3
COMPUTER
VIRUS
AND
IMMUNE
SYSTEM
----
60
4.5
EQ
AND
ETHICS
-----
61
4.5.1
EQ----
62
4.5.2
ETHICS
----
63
4.5.3
ACCOUNTABILITY
-----
65
4.6
PRIVACY
AND
ITS
RELATED
ISSUES
----
67
4.6.1
PRIVACY
----
67
4.6.2
TRANSPARENCY
AND
EXPLAINABILITY
68
4.7
COPYRIGHT
----
69
4.8
SINGULARITY
AND
OTHER
CONCERNS
----
72
4.8.1
SUPERINTELLIGENCE
AND
SINGULARITY
72
4.8.2
OTHER
CONCERNS
-----
75
REFERENCES
-
76
CHAPTER
5
AL
IN
LIFE:
FROM
CRADLE
TO
GRAVE
----
82
5.1
PREGNANCY
AND
POST-DELIVERY
-----83
5.1.1
INFERTILITY
TREATMENT
-----83
CONTENTS
-
XIII
5.1.2
5.1.3
5.2
5.3
5.4
5.5
5.5.1
5.5.2
SPERM
AND
EMBRYO
CULTURING
----
86
PREGNANT
WOMAN
SUPPORT
-
87
OBSTETRICS
AND
GYNECOLOGY
(OB/GYN)
----
88
PEDIATRICS
----
90
DAILY
LIFE
-
92
NCDS
AND
FRAILTY
----
93
NCDS
-----94
FRAILTY
----
95
REFERENCES
----
98
CHAPTER
6
AL
IN
QOL
(QUALITY
OF
LIVING),
QOS
(QUALITY
OF
SLEEPING),
AND
QOD
(QUALITY
OF
DYING)
----
101
6.1
6.1.1
6.1.2
6.2
6.2.1
6.2.2
6.2.3
6.2.4
6.3
QUALITY
OF
LIVING
(QOL)
----
101
QOL
BY
GENERAL
HEALTHCARE
----
103
QOL
BY
CHECKING
EXCRETIONS/SECRETIONS
----
104
QUALITY
OF
SLEEP
(QOS)
----
107
CHECKING
QUALITY
OF
SLEEP
----
108
HEADBAND
----
109
ARMBAND
----
109
BED
AND
MATTRESS
----
109
QUALITY
OF
DYING
(QOD)
----
110
REFERENCES
----
114
CHAPTER?
AL
IN
FOOD
INDUSTRY
----
118
7.1
7.1.1
7.1.2
7.2
7.2.1
7.2.2
7.3
7.3.1
7.3.2
7.3.3
7.3.4
7.4
7.4.1
7.4.2
7.5
FOOD
INDUSTRY
AND
BIODIVERSITY
----
118
FOOD
INDUSTRY
----
118
BIODIVERSITY
----
119
AGRICULTURE
INDUSTRY
----
120
OUTDOOR
FIELD
AGRICULTURE
----
120
INDOOR
VEGETABLE
FACTORY
----
122
ANIMAL
HUSBANDRY
----
124
LIVESTOCK
INDUSTRY
----
128
DAIRY
INDUSTRY
----
128
POULTRY
INDUSTRY
----
129
GIBIER
----
131
MARINE
PRODUCTS
INDUSTRY
----
132
NATURAL
OCEAN
FISH
CATCHING
----
132
AQUACULTURE
----
133
SUPPLY
MECHANISM
AND
DRONE
DELIVERY
----
136
XIV
CONTENTS
7.6
FUNCTIONAL
FOODS
----
137
7.7
FOOD
SAFETY
AND
WASTE
-----
140
7.8
AL-SUPPORTED
FOOD
TECHNOLOGY
----
142
7.9
YOU
ARE
WHAT
YOU
EAT
-----
143
REFERENCES
----
146
COFFEE
BREAK:
INFORMATION
DIABETES
-
153
REFERENCES
----
156
CHAPTER
8
AL
IN
PRACTICE
OF
MEDICINE
-
158
8.1
INTRODUCTION
----
158
8.2
AL
MEDICINE
VERSUS
ES
MEDICINE
-----
162
8.3
PREVENTIVE
MEDICINE
----
164
8.3.1
PREVENTION
----
164
8.3.2
PREDICTION
-----
168
8.4
DIAGNOSIS
-----
169
8.4.1
INTRODUCTION
----
169
8.4.2
DIAGNOSIS
-----
171
8.4.3
DIAGNOSIS
CASES
----
174
8.4.4
AL
DIAGNOSIS
VERSUS
DOCTOR
DIAGNOSIS
----
211
8.4.5
IATROGENESIS
----
217
8.5
TRIAGE
----
217
8.5.1
TRIAGE
IN
GENERAL
----
217
8.5.2
TRIAGE
IN
COVID-19
ERA
----
222
8.6
TREATMENT,
PRECISION
MEDICINE,
PAIN
MANAGEMENT
----
223
8.6.1
TREATMENT
CASES
----
223
8.6.2
PRECISION
MEDICINE
AND
EDGE-AI
-----
238
8.6.3
PAIN
MANAGEMENT
----
244
8.6.4
ALLERGY
----
253
8.6.5
DRUG
DEVELOPMENT
----
256
8.6.6
MEDICAL
CARE
OPERATIONS
----
256
8.6.7
SURGICAL
ROBOT
TECHNOLOGIES
-------
261
8.7
PROGNOSIS
----
264
8.7.1
DIAGNOSIS
AND
PROGNOSIS
-----
264
8.7.2
REMAINING
LIFE
PREDICTION
-----
267
8.8
SPORTS
MEDICINE
----
271
8.9
COSMETIC
SURGERY
----
273
8.10
CONCERNS
AND
FUTURE
----
274
8.10.1
CONCERNS
----
275
8.10.2
FUTURE
----
277
REFERENCES
----
277
CONTENTS
-
YY
XV
CHAPTER
9
AL
IN
PRACTICE
OF
DENTISTRY
-
302
9.1
DENTISTRY
VERSUS
MEDICINE
-----
302
9.2
AL
DENTISTRY
-----
304
9.2.1
DIGITAL
DENTISTRY
----
304
9.2.2
HEALTH
DATA
MANAGEMENT
-----
305
9.2.3
AL
DENTISTRY
-----
308
9.3
AL
DENTAL
DISCIPLINES
----
311
9.3.1
IMPLANTOLOGY
-----
311
9.3.2
PROSTHODONTICS
-----
313
9.3.3
ORTHODONTICS
-----
314
9.3.4
PERIODONTICS
-----
322
9.3.5
ENDODONTICS
-----
323
9.3.6
PEDIATRIC
DENTISTRY
----
324
9.3.7
ORAL
CANCERS
-----
325
9.3.8
RADIOLOGY
-----
325
9.4
AL
DENTAL
LABORATORY
AND
TECHNICIANS
----
328
9.5
CLINICAL
RECORDING
AND
DATA
SECURITY
----
330
9.5.1
SOAP
----
330
9.5.2
POS/POMR----
332
9.5.3
PKC
----
333
9.5.4
HIPAA
----
334
9.6
ADVANCED
DENTISTRY
IN
FUTURE
----
336
9.6.1
DENTISTRY
IN
GENERAL
----
336
9.6.2
DIGITAL
DENTISTRY
----
337
9.6.3
TELEDENTISTRY
----
340
9.6.4
SYSTEMIC
TREATMENT
----
342
REFERENCES
----
346
CHAPTER
10
AL
IN
DRUG
DEVELOPMENT
-
356
10.1
AL-ASSISTED
NEW
DRUG
DEVELOPMENT
----
357
10.1.1
DRUG
DESIGN
----
358
10.1.2
TARGET
IDENTIFICATION
----
360
10.1.3
LEAD
COMPOUND
IDENTIFICATION
----
362
10.1.4
CLINICAL
RESEARCH
----
364
10.1.5
OVERALL
----
366
10.1.6
COVID-19
VACCINE
DEVELOPMENT
-----
368
10.1.7
FUTURE
ACTIVITIES
----
370
10.2
AL-INCORPORATED
DRUG
DELIVERY
SYSTEMS
----
374
10.3
SIDE
EFFECT
AND
DRUG
REPOSITIONING
----
376
XVI
-
CONTENTS
10.3.1
SIDE
EFFECT
AND
ITS
PREDICTION
----
376
10.3.2
DRUG
REPOSITIONING
----
380
10.3.3
BIOSIMILAR
AND
GENERIC
DRUGS
-----
383
10.4
DRUG
INFORMATION
MANAGEMENT
AND
PHARMACIST
----
385
10.4.1
DRUG
INFORMATION
MANAGEMENT
-----
385
10.4.2
PRESCRIPTION
ERRORS
AND
MANAGEMENT
----
386
10.4.3
ROLE
OF
PHARMACISTS
-------
389
10.5
PLACEBO
EFFECT
AND
NOCEBO
EFFECT
-----
390
10.5.1
PLACEBO
EFFECT
-----
390
10.5.2
NOCEBO
EFFECT
-----
393
REFERENCES
----
395
CHAPTER
11
AL
IN
MATERIALS
SCIENCE
AND
DEVELOPMENT
-
402
11.1
AL-ASSISTED
MATERIALS
SCIENCE
-----
402
11.2
SMART
MATERIALS
----
404
11.3
AL-ASSISTED
MATERIALS
DESIGN
AND
DEVELOPMENT
-----
405
REFERENCES
-
411
CHAPTER
12
AL
IN
COVID-19
ERA,
INFODEMIC,
AND
POST-COVID-19
ERA
----
414
12.1
WITH
COVID-19
----
414
12.2
SOME
CONCERNS
AND
INFODEMIC
----
420
12.2.1
CONCERNS
----
420
12.2.2
INFODEMIC
----
422
12.3
POST
COVID-19
-----
424
REFERENCES
----
428
CHAPTER
13
AL
IN
FUTURE
----
431
13.1
PRESENT
AND
FUTURE
OF
AL
TECHNOLOGY
----
432
13.1.1
REINFORCEMENT
LEARNING
(RL)
----
432
13.1.2
GENERATIVE
ADVERSARIAL
NETWORKS
(GAN)
----
436
13.1.3
DRASTIC
CHANGE
IN
EMPLOYMENT
SECTOR
AND
SOCIETY
----
439
13.1.4
AUTOMATED
TRANSPORTATION
-----
440
13.2
ECOSYSTEM
----
442
13.3
BIOINFORMATICS
AND
ALIFE
-----
443
13.3.1
BIOINFORMATICS
----
443
13.3.2
ALIFE
----
446
13.4
MEDICINE
----
447
13.4.1
VOLUMETRIC
DISPLAY
TECHNOLOGY
----
447
13.4.2
PARITY
MIRROR
IMAGING
-----
450
CONTENTS
-
XVII
13.5
BRAIN-COMPUTER
INTERFACE
(BCI)
-
451
13.5.1
CONSCIOUSNESS
OF
ROBOT
----
451
13.5.2
HUMAN-ROBOT
INTERACTION
----
454
13.6
PREDICTION
AND
SINGULARITY
-
457
13.6.1
PREDICTION
BEFORE
SINGULARITY
----
457
13.6.2
SINGULARITY
AND
BEYOND
----
462
13.7
QUANTUM
COMPUTERS
----
463
REFERENCES
-
465
CLOSING
REMARKS
----
472
REFERENCES
----
473
INDEX
----
475
Contents Preface — V List of abbreviations — XIX About the Author-----XXIX Chapter 1 Al in general---- 1 1.1 Undefined definition---- 1 1.2 History of Al development and future---- 2 1.3 Nature-----5 1.3.1 Ingenerai----- 5 1.3.2 As a part of IT----- 7 1.4 Classification----- 8 1.4.1 Elemental technologies involved in Al----- 8 1.4.2 Three Als----- 11 1.5 Role, function, and applications of Al----- 13 1.5.1 Role---- 13 1.5.2 Function----- 14 1.5.3 Supporting technologies---- 14 1.5.4 Applications----- 17 1.6 Advantages and disadvantages —18 1.6.1 Advantages----- 18 1.6.2 Disadvantages---- 18 References-----19 Chapter 2 Al in information---- 23 2.1 Data versus information---- 23 2.1.1 Data---- 24 2.1.2 Data mining, information, and DIKW hierarchy 2.2 Knowledge, intelligence, and intellect---- 26 2.3 Al ontology-----29 References-----30 Chapter 3 Al in society---- 32 3.1 Global-----32 3.2 Societal---35
ХИ — 3.3 3.3.1 3.3.2 3.3.3 3.3.4 3.3.5 3.4 Contents Personal----- 37 Technological environment----- 37 Examples of jobs that are likely to be substituted by Al Representative examples of less likely positions to be substituted by Al---- 40 New-type jobs that Al creates----- 41 Work-style reformation-----42 Future of Al society----- 43 References---- 44 Chapter 4 Al in concern---- 47 Digital clone---- 47 4.1 Personality-----49 4.2 Legal personality---- 49 4.2.1 Personality---- 50 4.2.2 Consciousness, gender, and marriage-----50 4.2.3 IQ and common sense---- 52 4.3 IQ test---- 52 4.3.1 Common sense-----54 4.3.2 4.3.3 Lie and Sontaku-----55 4.4 Bias and errors-----57 4.4.1 Bias-----57 4.4.2 Errors---- 58 4.4.3 Computer virus and immune system-----60 4.5 EQ and ethics---- 61 4.5.1 EQ---- 62 4.5.2 Ethics---- 63 4.5.3 Accountability---- 65 4.6 Privacy and its related issues-----67 4.6.1 Privacy---- 67 4.6.2 Transparency and explainability-----68 4.7 Copyright-----69 4.8 Singularity and other concerns-----72 4.8.1 Superintelligent and singularity-----72 4.8.2 Other concerns-----75 References-----76 Chapter 5 Al in life: from cradle to grave---- 82 5-1 Pregnancy and post-delivery----- 83 5.1.1 Infertility treatment------83
Contents 5.1.2 5.1.3 5.2 5.3 5.4 5.5 5.5.1 5.5.2 Sperm and embryo culturing---- 86 Pregnant woman support-----87 Obstetrics and gynecology (OB/GYN)-----88 Pediatrics---- 90 Daily life---- 92 NCDs and frailty---- 93 NCDs---- 94 Frailty---- 95 References---- 98 Chapter 6 Al in QOL (quality of living), QOS (quality of sleeping), and QOD (quality of dying)---- 101 6.1 Quality of living (QOL)---- 101 6.1.1 QOL by general healthcare---- 103 6.1.2 QOL by checking excretions/secretions---- 104 6.2 Quality of sleep (QOS)----- 107 6.2.1 Checking quality of sleep---- 108 6.2.2 Headband---- 109 6.2.3 Armband---- 109 6.2.4 Bed and mattress---- 109 6.3 Quality of dying (QOD)------ 110 References---- 114 Chapter 7 Al in food industry---- 118 7.1 Food industry and biodiversity-----118 7.1.1 Food industry----- 118 7.1.2 Biodiversity----- 119 7.2 Agriculture industry---- 120 7.2.1 Outdoor field agriculture----- 120 7.2.2 Indoor vegetable factory----- 122 7.3 Animal husbandry----- 124 7.3.1 Livestock industry---- 128 7.3.2 Dairy industry----- 128 7.3.3 Poultry industry---- 129 7.3.4 Gibier---- 131 7.4 Marine products industry---- 132 7.4.1 Natural ocean fish catching---- 132 7.4.2 Aquaculture----- 133 7.5 Supply mechanism and drone delivery---- 136 XIII
XIV ----- 7.6 7.7 7.8 7.9 Contents Functional foods-—137 Food safety and waste —■ 140 Al-supported food technology------142 You are what you eat-----143 References---- 146 Coffee break: information diabetes----- 153 References---- 156 Chapter 8 Al in practice of medicine----- 158 8.1 8.2 8.3 8.3.1 8.3.2 8.4 8.4.1 8.4.2 8.4.3 8.4.4 8.4.5 8.5 8.5.1 8.5.2 8.6 8.6.1 8.6.2 8.6.3 8.6.4 8.6.5 8.6.6 8.6.7 8.7 8.7.1 8.7.2 8.8 8.9 8.10 8.10.1 8.10.2 Introduction-----158 Al medicine versus ES medicine-----162 Preventive medicine------ 164 Prevention---- 164 Prediction-----168 Diagnosis----- 169 Introduction-----169 Diagnosis----- 171 Diagnosis cases---- 174 Al diagnosis versus doctor diagnosis-----211 Iatrogenesis---- 217 Triage-----217 Triage in general---- 217 Triage in COVID-19 era----- 222 Treatment, precision medicine, pain management-----223 Treatment cases---- 223 Precision medicineand Edge-AI------238 Pain management-244 Allergy----- 253 Drug development----- 256 Medical care operations----- 256 Surgical robot technologies---- 261 Prognosis-----264 Diagnosis and prognosis------264 Remaining life prediction---- 267 Sports medicine----- 271 Cosmetic surgery-----273 Concerns and future----- 274 Concerns---- 275 Future----- 277 References-----277
Chapter 9 Al in practice of dentistry----- 302 9.1 9.2 Dentistry versus medicine----- 302 Al dentistry----- 304 9.2.1 Digital dentistry----- 304 9.2.2 Health data management----- 305 9.2.3 Al dentistry------ 308 9.3 9.3.1 Al dental disciplines----- 311 Implantology------ 311 9.3.2 Prosthodontics----- 313 9.3.3 Orthodontics------ 314 9.3.4 Periodontics------322 9.3.5 Endodontics------ 323 9.3.6 Pediatric dentistry----- 324 9.3.7 Oral cancers------ 325 9.3.8 Radiology----- 325 9.4 Al dental laboratory and technicians----- 328 9.5 9.5.1 Clinical recording and data security----- 330 SOAP----- 330 9.5.2 POS/POMR------ 332 9.5.3 PKC----- 333 9.5.4 HIPAA----- 334 9.6 Advanced dentistry in future----- 336 9.6.1 Dentistry in general — 336 9.6.2 Digital dentistry----- 337 9.6.3 Teledentistry------ 340 9.6.4 Systemic treatment----- 342 References----- 346 Chapter 10 Al in drug development — 356 10.1 Al-assisted new drug development----- 357 10.1.1 Drug design----- 358 10.1.2 Target identification — 360 10.1.3 Lead compound identification----- 362 10.1.4 Clinical research----- 364 10.1.5 Overall----- 366 10.1.6 10.1.7 COVID-19 vaccine development----- 368 Future activities----- 370 10.2 Al-incorporated drug delivery systems-----374 10.3 Side effect and drug repositioning----- 376
XVI ---- 10.3.1 10.3.2 10.3.3 10.4 10.4.1 10.4.2 10.4.3 10.5 10.5.1 10.5.2 Contents Side effect and its prediction----- 376 Drug repositioning---- 380 Biosimilar and generic drugs----- 383 Drug information management and pharmacist Drug information management-----385 Prescription errors and management-----386 Role of pharmacists---- 389 Placebo effect and nocebo effect-----390 Placebo effect---- 390 Nocebo effect---- 393 References---- 395 385 Chapter 11 Al in materials science and development-----402 11.1 Al-assisted materials science---- 402 11.2 Smart materials-----404 11.3 Al-assisted materials design and development------ 405 References-----411 Chapter 12 Al in COVID -19 era, infodemic, and post-COVID-19 era 12.1 With COVID-19---- 414 12.2 Some concerns and infodemic-----420 12.2.1 Concerns---- 420 12.2.2 Infodemic---- 422 12.3 Post COVID-19---- 424 References---- 428 Chapter 13 Al in future ---- 431 13.1 Present and future of Al technology-----432 13.1.1 Reinforcement learning (RL)-----432 13.1.2 Generative adversarial networks (GAN)-----436 13.1.3 Drastic change in employment sector and society-----439 13.1.4 Automated transportation---- 440 13.2 Ecosystem---- 442 13.3 Bioinformatics and ALife-----443 13.3.1 Bioinformatics---- 443 13.3.2 ALife---- 446 13.4 Medicine-----447 13.4.1 Volumetric display technology---- 447 13.4.2 Parity mirror imaging---- 450
Contents 13.5 13.5.1 13.5.2 13.6 13.6.1 13.6.2 13.7 Brain-computer interface (ВСІ)-----451 Consciousness of robot------451 Human-robot interaction------454 Prediction and singularity------457 Prediction before singularity-----457 Singularity and beyond------462 Quantum computers-----463 References-----465 Closing remarks----- 472 References-----473 Index----- 475 — XVII |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author | Oshida, Yoshiki |
| author_GND | (DE-588)1225432790 |
| author_facet | Oshida, Yoshiki |
| author_role | aut |
| author_sort | Oshida, Yoshiki |
| author_variant | y o yo |
| building | Verbundindex |
| bvnumber | BV047583848 |
| classification_rvk | XC 4000 |
| ctrlnum | (OCoLC)1286877087 (DE-599)DNB1226451152 |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a22000008c 4500</leader><controlfield tag="001">BV047583848</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20231212</controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">211111s2022 gw a||| |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">21,N06</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1226451152</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783110717792</subfield><subfield code="c">: EUR 86.95 (DE) (freier Preis), EUR 86.95 (AT) (freier Preis)</subfield><subfield code="9">978-3-11-071779-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3110717794</subfield><subfield code="9">3-11-071779-4</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783110717792</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1286877087</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1226451152</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-384</subfield><subfield code="a">DE-573</subfield><subfield code="a">DE-898</subfield><subfield code="a">DE-29T</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-M347</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XC 4000</subfield><subfield code="0">(DE-625)152514:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">660</subfield><subfield code="2">23sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Oshida, Yoshiki</subfield><subfield code="0">(DE-588)1225432790</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Artificial intelligence for medicine</subfield><subfield code="b">people, society, pharmaceuticals, and medical materials</subfield><subfield code="c">Yoshiki Oshida</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin</subfield><subfield code="b">De Gruyter</subfield><subfield code="c">[2022]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXVII, 490 Seiten</subfield><subfield code="b">Illustrationen</subfield><subfield code="c">24 cm x 17 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">De Gruyter STEM</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Künstliche Intelligenz</subfield><subfield code="0">(DE-588)4033447-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Medizin</subfield><subfield code="0">(DE-588)4038243-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Gesellschaft</subfield><subfield code="0">(DE-588)4020588-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Medizinische Versorgung</subfield><subfield code="0">(DE-588)4038270-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Intelligenter Werkstoff</subfield><subfield code="0">(DE-588)4274825-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Künstliche Intelligenz</subfield><subfield code="0">(DE-588)4033447-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Medizinische Versorgung</subfield><subfield code="0">(DE-588)4038270-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Gesellschaft</subfield><subfield code="0">(DE-588)4020588-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="4"><subfield code="a">Intelligenter Werkstoff</subfield><subfield code="0">(DE-588)4274825-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Medizin</subfield><subfield code="0">(DE-588)4038243-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Künstliche Intelligenz</subfield><subfield code="0">(DE-588)4033447-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Walter de Gruyter GmbH & Co. KG</subfield><subfield code="0">(DE-588)10095502-2</subfield><subfield code="4">pbl</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield><subfield code="z">978-3-11-071785-3</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield><subfield code="z">978-3-11-071792-1</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">X:MVB</subfield><subfield code="u">https://www.degruyter.com/books/9783110717792</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032969182&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Augsburg - ADAM Catalogue Enrichment</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032969182&sequence=000003&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-032969182</subfield></datafield></record></collection> |
| id | DE-604.BV047583848 |
| illustrated | Illustrated |
| index_date | 2024-07-03T18:34:05Z |
| indexdate | 2024-11-27T15:01:16Z |
| institution | BVB |
| institution_GND | (DE-588)10095502-2 |
| isbn | 9783110717792 3110717794 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-032969182 |
| oclc_num | 1286877087 |
| open_access_boolean | |
| owner | DE-384 DE-573 DE-898 DE-BY-UBR DE-29T DE-29 DE-M347 |
| owner_facet | DE-384 DE-573 DE-898 DE-BY-UBR DE-29T DE-29 DE-M347 |
| physical | XXVII, 490 Seiten Illustrationen 24 cm x 17 cm |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | De Gruyter |
| record_format | marc |
| series2 | De Gruyter STEM |
| spelling | Oshida, Yoshiki (DE-588)1225432790 aut Artificial intelligence for medicine people, society, pharmaceuticals, and medical materials Yoshiki Oshida Berlin De Gruyter [2022] XXVII, 490 Seiten Illustrationen 24 cm x 17 cm txt rdacontent n rdamedia nc rdacarrier De Gruyter STEM Künstliche Intelligenz (DE-588)4033447-8 gnd rswk-swf Medizin (DE-588)4038243-6 gnd rswk-swf Arzneimittel (DE-588)4003115-9 gnd rswk-swf Gesellschaft (DE-588)4020588-5 gnd rswk-swf Medizinische Versorgung (DE-588)4038270-9 gnd rswk-swf Intelligenter Werkstoff (DE-588)4274825-2 gnd rswk-swf Künstliche Intelligenz (DE-588)4033447-8 s Medizinische Versorgung (DE-588)4038270-9 s Gesellschaft (DE-588)4020588-5 s Arzneimittel (DE-588)4003115-9 s Intelligenter Werkstoff (DE-588)4274825-2 s DE-604 Medizin (DE-588)4038243-6 s Walter de Gruyter GmbH & Co. KG (DE-588)10095502-2 pbl Erscheint auch als Online-Ausgabe 978-3-11-071785-3 Erscheint auch als Online-Ausgabe 978-3-11-071792-1 X:MVB https://www.degruyter.com/books/9783110717792 DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032969182&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis Digitalisierung UB Augsburg - ADAM Catalogue Enrichment application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032969182&sequence=000003&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Oshida, Yoshiki Artificial intelligence for medicine people, society, pharmaceuticals, and medical materials Künstliche Intelligenz (DE-588)4033447-8 gnd Medizin (DE-588)4038243-6 gnd Arzneimittel (DE-588)4003115-9 gnd Gesellschaft (DE-588)4020588-5 gnd Medizinische Versorgung (DE-588)4038270-9 gnd Intelligenter Werkstoff (DE-588)4274825-2 gnd |
| subject_GND | (DE-588)4033447-8 (DE-588)4038243-6 (DE-588)4003115-9 (DE-588)4020588-5 (DE-588)4038270-9 (DE-588)4274825-2 |
| title | Artificial intelligence for medicine people, society, pharmaceuticals, and medical materials |
| title_auth | Artificial intelligence for medicine people, society, pharmaceuticals, and medical materials |
| title_exact_search | Artificial intelligence for medicine people, society, pharmaceuticals, and medical materials |
| title_exact_search_txtP | Artificial intelligence for medicine people, society, pharmaceuticals, and medical materials |
| title_full | Artificial intelligence for medicine people, society, pharmaceuticals, and medical materials Yoshiki Oshida |
| title_fullStr | Artificial intelligence for medicine people, society, pharmaceuticals, and medical materials Yoshiki Oshida |
| title_full_unstemmed | Artificial intelligence for medicine people, society, pharmaceuticals, and medical materials Yoshiki Oshida |
| title_short | Artificial intelligence for medicine |
| title_sort | artificial intelligence for medicine people society pharmaceuticals and medical materials |
| title_sub | people, society, pharmaceuticals, and medical materials |
| topic | Künstliche Intelligenz (DE-588)4033447-8 gnd Medizin (DE-588)4038243-6 gnd Arzneimittel (DE-588)4003115-9 gnd Gesellschaft (DE-588)4020588-5 gnd Medizinische Versorgung (DE-588)4038270-9 gnd Intelligenter Werkstoff (DE-588)4274825-2 gnd |
| topic_facet | Künstliche Intelligenz Medizin Arzneimittel Gesellschaft Medizinische Versorgung Intelligenter Werkstoff |
| url | https://www.degruyter.com/books/9783110717792 http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032969182&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032969182&sequence=000003&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT oshidayoshiki artificialintelligenceformedicinepeoplesocietypharmaceuticalsandmedicalmaterials AT walterdegruytergmbhcokg artificialintelligenceformedicinepeoplesocietypharmaceuticalsandmedicalmaterials |
Es ist kein Print-Exemplar vorhanden.
Inhaltsverzeichnis